Clazakizumab Biosimilar - Research Grade

Human

IL-6

>1mg/ml

Human IgG1

Siltuximab Biosimilar - Research Grade (ICH5104), Olokizumab Biosimilar - Research Grade (ICH5170), Elsilimomab Biosimilar - Research Grade (ICH5516), Pacibekitug Biosimilar - Research Grade (ICH5751), Sirukumab Biosimilar - Research Grade (ICH5869), Vamikibart Biosimilar - Research Grade (ICH5966), Ziltivekimab Biosimilar - Research Grade (ICH6008)

https://www.imgt.org/mAb-DB/

ICH3002

P05231

3569

RRID:AB_2921605

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of clazakizumab, a humanized monoclonal antibody directed against interleukin-6 (IL-6). It is supplied as a research-use-only (RUO) reagent and is not the clinical drug, nor is it intended for human or veterinary use. Built as a human IgG1 that binds the IL-6 cytokine, it is intended to recapitulate the antigen-binding behaviour of the originator so researchers can study IL-6 neutralisation in controlled systems. Typical applications include in-vitro blockade of IL-6 signalling, use as a positive/reference control in binding and neutralisation assays, epitope and affinity characterisation, and as a benchmark antibody in biosimilarity or developability workflows. Manufactured to research grade with low endotoxin (<1 EU/mg standard; ultra-low <0.5 EU/mg options) and available in bulk milligram-to-gram quantities, it supports assay development, in-vitro mechanistic studies, and preclinical formatting work. Note that this is an anti-cytokine biosimilar analog, distinct from anti-IL-6-receptor antibodies such as tocilizumab, which target the receptor rather than the ligand. Interleukin-6 (IL-6; UniProt P05231) is a pleiotropic ~21-26 kDa four-helix-bundle cytokine central to inflammation, acute-phase responses, and immune regulation. It is produced by many cell types, including macrophages, T cells, fibroblasts, and endothelial cells. IL-6 signals through two modes: classic signalling, in which it binds the membrane IL-6 receptor (IL-6R/CD126) on hepatocytes and leukocytes; and trans-signalling, in which IL-6 complexed with soluble IL-6R engages the ubiquitously expressed signal-transducing subunit gp130 (IL6ST). Both routes drive gp130 dimerisation and activation of the JAK/STAT3, SHP2/MAPK, and PI3K pathways. Downstream effects include hepatic C-reactive protein production, B-cell and plasma-cell differentiation, Th17 polarisation, and osteoclast activity. Dysregulated IL-6 contributes to rheumatoid arthritis, cytokine release syndrome, and other inflammatory conditions, making the ligand a well-validated therapeutic and research target.

B-cell stimulatory factor 2, BSF-2, CTL differentiation factor, CDF, Hybridoma growth factor, Interferon beta-2, IFN-beta-2, Interleukin-6, IFNB2

Detects human IL-6. This non-therapeutic antibody uses the same sequence as the therapeutic antibody Clazakizumab.

This monoclonal antibody was purified using multi-step affinity chromatography methods such as Protein A or G depending on the species and isotype.

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

Clazakizumab (anti-IL-6) Biosimilar

Q: Is the Clazakizumab biosimilar available in gram quantities?

A: Yes — it is supplied in scalable milligram to gram quantities for heavy-usage and high-throughput laboratories.

Q: Is this research-grade Clazakizumab suitable for in vivo studies?

A: Yes, it is a low-endotoxin, in vivo-ready formulation intended for preclinical and in vivo research use only (RUO).

Q: What does the Clazakizumab biosimilar target?

A: It is an unconjugated, non-therapeutic analog of Clazakizumab that binds human IL-6.